Biotech Investment Analyst — Drug Asset & Assessment

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work

creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.

• Create and critique rubrics that analyze commercial drugs and drug-development programs.
• Provide overall company and asset assessment mechanism, clinical data, competitive position, and value drivers.
• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions.
• Apply your assessment across the pilot's set of companies (~5–10).

• US-based biotech / healthcare investment analyst with a specialist-fund background.
• Familiarity with biotech/pharma development programs.
• Able to assess a drug asset and the company behind it end-to-end.
• 5+ years evaluating biotech/pharma companies or assets.

Engagement Details:
Duration:
Approximately 10–20 hours over a 1–2 week pilot. Remote.

US-based.

Why Participate:
Help improve expert AI evaluation of drugs and drug-development programs. Recurring engagement for strong contributors.

AI evaluation Clinical reasoning Research

This opportunity may suit professionals with relevant experience in AI evaluation, Clinical reasoning, Research. Review the official description and requirements before applying.

The listing states $120 - $200 / hour. Confirm the final rate, workload, and payment terms during the official application process.

• You can show recent, specific work involving AI evaluation, Clinical reasoning, Research.
• The listed commitment of 15 hours/week fits your schedule.
• You can communicate your reasoning clearly in the application language.
• You are comfortable with project availability and hours varying over time.